Beam Therapeutics Inc. Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale
Beam Therapeutics Inc. (BEAM) reported Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale of $354.29 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities · last filed 2026-08-04
- Beam Therapeutics Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2026-06-30 was $173.00M, a 3.80% increase year-over-year.
- Beam Therapeutics Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2026-03-31 was $181.29M, a 16.51% decline year-over-year.
- Beam Therapeutics Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2025-12-31 was $218.03M, a 68.69% increase year-over-year.
- Beam Therapeutics Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2025-09-30 was $240.64M, a 31.50% increase year-over-year.
- Beam Therapeutics Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2025 was $842.49M, a 23.82% increase from fiscal 2024.
- Beam Therapeutics Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2024 was $680.39M, a 37.57% decline from fiscal 2023.
- Beam Therapeutics Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2023 was $1.09B, a 9.52% decline from fiscal 2022.
- Beam Therapeutics Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2022 was $1.20B, a 127.60% increase from fiscal 2021.
| Period end | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 3 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 6 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 9 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $173.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $354.29M 10-Q · filed 2026-08-04 | $572.33M derived: sum of 3 quarters · filed 2026-08-04 | $812.97M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $181.29M 10-Q · filed 2026-05-07 | $399.33M derived: sum of 2 quarters · filed 2026-05-07 | $639.97M derived: sum of 3 quarters · filed 2026-05-07 | $806.64M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $218.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $458.68M derived: sum of 2 quarters · filed 2026-02-24 | $625.34M derived: sum of 3 quarters · filed 2026-08-04 | $842.49M 10-K · filed 2026-02-24 |
| 2025-09-30 | $240.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $407.31M derived: sum of 2 quarters · filed 2026-08-04 | $624.46M 10-Q · filed 2025-11-04 | $753.71M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $166.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $383.81M 10-Q · filed 2026-08-04 | $513.06M derived: sum of 3 quarters · filed 2026-08-04 | $696.06M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $217.15M 10-Q · filed 2026-05-07 | $346.39M derived: sum of 2 quarters · filed 2026-05-07 | $529.39M derived: sum of 3 quarters · filed 2026-05-07 | $753.32M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $129.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $312.25M derived: sum of 2 quarters · filed 2026-02-24 | $536.18M derived: sum of 3 quarters · filed 2026-02-24 | $680.39M 10-K · filed 2026-02-24 |
| 2024-09-30 | $183.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $406.93M derived: sum of 2 quarters · filed 2025-11-04 | $551.14M 10-Q · filed 2025-11-04 | $706.10M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $223.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $368.14M 10-Q · filed 2025-08-05 | $523.10M derived: sum of 3 quarters · filed 2026-02-24 | $794.53M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $144.22M 10-Q · filed 2025-05-06 | $299.18M derived: sum of 2 quarters · filed 2026-02-24 | $570.60M derived: sum of 3 quarters · filed 2026-02-24 | $936.13M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $154.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $426.38M derived: sum of 2 quarters · filed 2026-02-24 | $791.91M derived: sum of 3 quarters · filed 2026-02-24 | $1.09B 10-K · filed 2026-02-24 |
| 2023-09-30 | $271.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $636.95M derived: sum of 2 quarters · filed 2024-11-05 | $934.95M 10-Q · filed 2024-11-05 | $1.30B derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $365.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $663.52M 10-Q · filed 2024-08-06 | $1.02B derived: sum of 3 quarters · filed 2025-02-25 | $1.36B derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $298.00M 10-Q · filed 2024-05-07 | $658.09M derived: sum of 2 quarters · filed 2025-02-25 | $991.73M derived: sum of 3 quarters · filed 2025-02-25 | $1.34B derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $360.09M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $693.73M derived: sum of 2 quarters · filed 2025-02-25 | $1.04B derived: sum of 3 quarters · filed 2025-02-25 | $1.20B 10-K · filed 2025-02-25 |
| 2022-09-30 | $333.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $684.21M derived: sum of 2 quarters · filed 2023-11-08 | $844.52M 10-Q · filed 2023-11-08 | $950.87M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $350.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $510.88M 10-Q · filed 2023-08-08 | $617.23M derived: sum of 3 quarters · filed 2024-02-27 | $877.63M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $160.31M 10-Q · filed 2023-05-10 | $266.66M derived: sum of 2 quarters · filed 2024-02-27 | $527.05M derived: sum of 3 quarters · filed 2024-02-27 | $669.13M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $106.35M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $366.75M derived: sum of 2 quarters · filed 2024-02-27 | $508.82M derived: sum of 3 quarters · filed 2024-02-27 | $529.27M 10-K · filed 2024-02-27 |
| 2021-09-30 | $260.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $402.47M derived: sum of 2 quarters · filed 2022-11-07 | $422.92M 10-Q · filed 2022-11-07 | $464.14M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $142.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $162.53M 10-Q · filed 2022-08-09 | $203.74M derived: sum of 3 quarters · filed 2023-02-28 | $272.92M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $20.45M 10-Q · filed 2022-05-09 | $61.67M derived: sum of 2 quarters · filed 2023-02-28 | $130.85M derived: sum of 3 quarters · filed 2023-02-28 | |
| 2020-12-31 | $41.22M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $110.40M derived: sum of 2 quarters · filed 2023-02-28 | $198.60M 10-K · filed 2023-02-28 | |
| 2020-09-30 | $69.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $157.38M 10-Q · filed 2021-11-08 | ||
| 2020-06-30 | $88.20M 10-Q · filed 2021-08-10 | |||
| 2019-12-31 | $76.07M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |